Terug
37
Dagbereik
€ 19,30
€ 19,83
52-Weeksbereik
€ 9,13
€ 22,98
Volume
608.198
50D / 200D Gem.
€ 19,94
/
€ 17,19
Vorige Slotkoers
€ 18,97
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 23,3 | 0,4 |
| P/B | 2,7 | 2,9 |
| ROE % | 11,7 | 3,7 |
| Net Margin % | 3,2 | 3,8 |
| Rev Growth 5Y % | 2,9 | 10,0 |
| D/E | 0,1 | 0,2 |
Belangrijkste Punten
Revenue grew 2,85% annually over 5 years — modest growth
Earnings grew 49,63% over the past year
ROE of 11,69% — decent returns on equity
Debt/Equity of 0,05 — conservative balance sheet
Generating 139,15M in free cash flow
PEG of 0,45 suggests growth is underpriced
Groei
Revenue Growth (5Y)
2,85%
Revenue (1Y)7,08%
Earnings (1Y)49,63%
FCF Growth (3Y)91,13%
Kwaliteit
Return on Equity
11,69%
ROIC6,81%
Net Margin3,21%
Op. Margin2,64%
Veiligheid
Debt / Equity
0,05
Current Ratio3,38
Interest Coverage30,72
Waardering
P/E Ratio
23,30
P/B Ratio2,70
EV/EBITDA25,54
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 7,08% | Revenue Growth (3Y) | 4,84% |
| Earnings Growth (1Y) | 49,63% | Earnings Growth (3Y) | 24,04% |
| Revenue Growth (5Y) | 2,85% | Earnings Growth (5Y) | 5,02% |
| Profitability | |||
| Revenue (TTM) | 1,84B | Net Income (TTM) | 59,06M |
| ROE | 11,69% | ROA | 7,31% |
| Gross Margin | 13,03% | Operating Margin | 2,64% |
| Net Margin | 3,21% | Free Cash Flow (TTM) | 139,15M |
| ROIC | 6,81% | FCF Growth (3Y) | 91,13% |
| Safety | |||
| Debt / Equity | 0,05 | Current Ratio | 3,38 |
| Interest Coverage | 30,72 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 23,30 | P/B Ratio | 2,70 |
| P/S Ratio | 0,75 | PEG Ratio | 0,45 |
| EV/EBITDA | 25,54 | Dividend Yield | 0,00% |
| Market Cap | 1,38B | Enterprise Value | 1,24B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1,84B | 1,72B | 1,67B | 1,69B | 1,64B |
| Net Income | 59,06M | 39,47M | 38,39M | 34,24M | 48,54M |
| EPS (Diluted) | 0,81 | 0,53 | 0,52 | 0,46 | 0,65 |
| Gross Profit | 239,41M | 228,09M | 214,75M | 193,31M | 230,57M |
| Operating Income | 48,54M | 53,27M | 54,66M | 43,79M | 64,13M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 807,78M | 815,47M | 803,18M | 718,33M | 786,80M |
| Total Liabilities | 297,57M | 315,55M | 346,57M | 292,16M | 334,12M |
| Shareholders' Equity | 510,21M | 499,93M | 456,62M | 426,17M | 452,68M |
| Total Debt | 24,68M | 16,43M | 43,64M | 33,10M | 17,80M |
| Cash & Equivalents | 161,12M | 85,24M | 54,33M | 26,28M | 70,79M |
| Current Assets | 576,42M | 556,65M | 571,70M | 508,63M | 546,38M |
| Current Liabilities | 170,38M | 192,55M | 216,93M | 178,62M | 191,13M |
Strategiescores
This stock passed the criteria for 1 strategy
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#684 of 1024
Recente Activiteit
Ingestapt
Cash Flow Compounder
Mar 24, 2026